First author [reference] | Year | Study subjects | Outcome measure(s) | Results |
Hugh-Jones [28] | 1987 | 15 patients, squamous cell carcinoma | Airway obstruction | Complete relief of obstruction in 25%, partial relief in remaining 75% |
Kato [17] | 1996 | 240 patients, bronchogenic carcinoma | Complete remission | Complete remission obtained in 83.2% of early-stage lesions |
Cortese [29] | 1997 | 21 patients, squamous cell carcinoma | Complete response | Complete response lasting 12 months obtained in 52% |
McCaughan [24] | 1997 | 175 patients with NSCLC | Survival, KPS | Median survival by clinical stage: IIIa 5.7 months, IIIb 5.5 months, IV 5 months; KPS had significant impact on survival |
Moghissi [20] | 1999 | 100 patients: 90 with NSCLC, 10 SCLC | Percentage of obstruction, FVC, FEV1, WHO performance status | 67% mean improvement in obstruction, improvements in FEV1, FVC and performance status |
Diaz-Jiménez [30] | 1999 | 14 patients with NSCLC | Time to recurrence, symptoms compared to Nd-YAG laser resection | Similar efficacy, PDT showed longer time to treatment failure (50 versus 38 days) |
Moghissi [31] | 2007 | 21 patients, early central lung cancer, NSCLC | Complete response, survival | Complete response in 100%, mean survival 39.3 months |
Minnich [32] | 2010 | 133 patients, NSCLC | Mean mMRC dyspnoea scale, complications, survival | Mean mMRC improved from 3 to 2.7, complications in 15%, median survival 4.4 years |
Cai [33] | 2013 | 30 patients, NSCLC | Total response, mean tumour obstruction, KPS | Total response in 86.7%, mean tumour obstruction decreased from 90% to 16.7%, mean KPS increased from 40 to 80 |
NSCLC: nonsmall cell lung cancer; KPS: Karnofsky Performance Score; SCC: small cell lung cancer; FVC: forced vital capacity; FEV1: forced expiratory volume in 1 s; WHO: World Health Organization; Nd-YAG: neodymium-doped yttrium aluminium garnet; mMRC: modified Medical Research Council.